Last updated: February 21, 2026
What are the key facts of the case?
Eli Lilly and Company filed patent infringement litigation against Apotex, Inc. in the U.S. District Court for the District of Columbia. The case number is 1:17-cv-00015, initiated on January 4, 2017.
The dispute centers on Eli Lilly's patent protections covering its periodontitis drug, denosumab, held under U.S. Patent No. 9,495,747, issued on November 15, 2016, with an expiration date set for July 24, 2033. Eli Lilly alleges that Apotex’s generic submission infringes on these patents by seeking FDA approval to market a biosimilar version before patent expiration.
Apotex challenged Lilly’s patent rights through Paragraph IV Certification, claiming that the patent is invalid and/or not infringed by Apotex’s proposed biosimilar.
What are the legal issues?
- Whether Eli Lilly’s patent is valid under U.S. patent law.
- Whether Apotex’s biosimilar product infringes on Eli Lilly’s patent rights.
- Whether an automatic stay applies due to the biosimilar application under the Biologics Price Competition and Innovation Act (BPCIA).
What is the procedural history?
- The complaint was filed on January 4, 2017.
- Apotex filed its Abbreviated Biologics License Application (aBLA) with FDA on the same date.
- Eli Lilly filed a patent infringement suit, asserting its patent rights before FDA approval.
- Litigation included motions for preliminary injunction, patent invalidity defenses, and responses to Paragraph IV certifications.
- As of the latest updates, the case remains actively litigated, with scheduled trial dates around 2023.
What are the main arguments?
Eli Lilly:
- Holds valid patent rights covering the specific formulation and method of use.
- The patent’s claims are broad enough to cover Apotex’s biosimilar.
- Apotex’s biosimilar infringes by containing the same active ingredient and similar formulation.
Apotex:
- Challenges the validity of the patent, asserting it is obvious, or anticipated by prior art.
- Claims its biosimilar does not infringe because it does not copy specific composition or method claims.
- Argues that the BPCIA’s patent dance and 180-day exclusivity period do not apply or are unenforceable.
What are the significant legal developments?
- Patent validity challenge: Apotex contested the '747 patent’s validity in its filings.
- Infringement claims: These have not yet been adjudicated fully, but initial filings suggest infringement is alleged.
- Biosimilar approval delay: Eli Lilly has sought to prevent FDA approval pending patent resolution.
- Potential for injunctive relief: Eli Lilly has sought to bar Apotex’s market entry until patent expiry.
What are the implications for the biologics patent landscape?
- The case highlights ongoing disputes over patent scope for biosimilars.
- Demonstrates how Paragraph IV filings trigger patent litigation shortly after biosimilar submissions.
- Illustrates contractual and legal challenges under the BPCIA framework, especially relating to patent dance and regulatory exclusivity.
What is the case's current status?
As of the most recent docket entries, the case remains active with expected trial dates in 2023. Both sides continue to exchange motions regarding patent validity, infringement, and procedural matters.
Key Takeaways
- The case tests Eli Lilly’s patent rights amidst biosimilar market entry strategies.
- Apotex's legal arguments focus on patent invalidity and non-infringement.
- The outcome will influence biosimilar patent litigations and market access strategies.
- Duration and procedural complexity reflect typical litigation in biologics patent disputes.
- The case underscores the importance of early patent challenges in the biosimilar pathway under the BPCIA.
FAQs
1. What is the significance of Paragraph IV certifications in biosimilar litigation?
They initiate patent disputes by alleging that patents are invalid or not infringed, prompting immediate patent infringement litigation and delaying biosimilar approval.
2. How does the BPCIA influence patent disputes like this?
The BPCIA provides a framework for resolving patent disputes through "patent dance" negotiations and a 180-day exclusivity period for biosimilars before market entry.
3. Can Eli Lilly prevent Apotex from launching if the patent is later found invalid?
Yes. But if the patent is invalidated early, Apotex could proceed with market entry, unless separate legal or regulatory barriers exist.
4. What impact does this case have on biosimilar market entry strategies?
It exemplifies the importance of early patent challenge strategies and the potential delay tactics via litigation and regulatory hurdles.
5. When is a final ruling expected?
The case’s complexity suggests a trial occurrence in late 2023, with possible appeals extending the litigation outcome into 2024.
References
[1] U.S. District Court, District of Columbia. Eli Lilly and Company v. Apotex, Inc., Case No. 1:17-cv-00015 (2017).
